Helixgate https://validator.w3.org/feed/docs/rss2.html Trump administration sued over visa time limit that would affect grad students, postdocs Header STAT+: The White House declares ‘promises made, promises kept’ on lowering drug prices. Nice try Embedding Regulatory Strategy in Cell and Gene Therapy Development STAT+: Real-world psilocybin data suggest need for close monitoring STAT+: Leaders of Mass General, Dana-Farber among hospital execs who got big raises in 2024 Home Trump is taking credit for lower list prices. But a Biden-era law did a lot of the heavy lifting BioMarin acquires experimental drug for rare bone disorder in $275M deal AstraZeneca’s win in lung cancer; Sandoz inks a China deal Exercise-Boosting Molecule May Help Improve Muscle Health in Type 2 Diabetes Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drug Rebounding biotech funds expected to spur CDMO growth within year Regeneron ends eye disease study due to antibody’s safety profile Amylyx’s bet on a GLP-1 blocker pays off Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemia STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass Opinion: In parts of the world, antibiotic overuse isn’t the problem — underuse is Assessing shared failures with AI is key to cell and gene therapy’s evolution Albumin-Fused Antibodies May Reduce Fetal Exposure to Therapeutics Malaria Mosquito Bites Turned Into Immune Boosters in New Chemovaccination Strategy STAT+: Sanofi to lay off 229 workers in Mass., a year after $9.1B Blueprint Medicines acquisition STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise The Microbiome Field Enters Its Next Chapter Pharma Races to Scale AI as Billions Flow into Drug Discovery Argenx jumps on Phase 3 data for blockbuster Vyvgart EyePoint plummets on pivotal data for main drug Roundup: Removing Impurities from Biomanufacturing STAT+: The IRS is probing UnitedHealth, and a private equity slowdown EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race Regeneron ends eye disease trial for anti-CD3 antibody following safety review STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit Your AI Is Only as Good as Your Inputs AstraZeneca pulls plug on late-stage lung cancer trial, extending losing streak Everything the Trump administration did on health care last week Vera’s newly approved IgA nephropathy drug supports kidney function, like Otsuka’s Voyxact Glioblastoma therapy timing could be key to treatment J&J hands lymphoma bispecific CAR T back to AbelZeta Malaria-Causing Plasmodium in Uganda Show Rapid Spread of Drug Resistance Mutations STAT+: Epic confronts unprecedented challenges as it prepares to address customers and unveil road map Italian biotech gains momentum as VC funding, tech transfer environment improve Animals have been eating nature’s original bioplastic for millions of years How AI-enabled Software as Medical Devices are Reshaping Regulatory Routes and Medicine STAT+: State laws may be curbing private equity takeovers of physician group Living circuit boards built by printing bacterial transistors A scalable platform to discover and characterize substrates of molecular glue degraders CDMOs Expand and Build for Future Growth University of Rhode Island Wins Grant to Study Cerebral Amyloid Angiopathy Prevalent in Alzheimer’s Patients